February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Related news and resources
#AlwaysInnovating: Pharmaceutical Industry Facts & Figures
This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...
Read more
Resumed 12th session of the Intergovernmental Negotiating Body (INB 12)
On 2 December 2024 in Geneva, IFPMA delivered a statement at the resumed INB 12.
Read moreIFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers
The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read more